nach oben

Erschienen in:

04.03.2023 | Review Article

Peritoneal Mesothelioma: Systematic Review of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Protocol Outcomes

verfasst von: Vahan Kepenekian, Olivia Sgarbura, Frederic Marchal, Laurent Villeneuve, Olivier Glehen, Shigeki Kusamura, Marcello Deraco

Erschienen in: Indian Journal of Surgical Oncology | Sonderheft 1/2023

Einloggen, um Zugang zu erhalten

Abstract

Diffuse malignant peritoneal mesothelioma (DMPM) prognosis was improved by the locoregional treatment combining cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). HIPEC is a multiparametric treatment with multiple protocols proposed and reviewed in this work. A systematic review of medical literature was performed according to PRISMA guidelines. The search strategy used “malignant peritoneal mesothelioma” and “HIPEC” as keywords in three databases. Studies were included if reporting precisely the HIPEC regimen and the related outcomes, if comparing regimen, or if reporting national/international guidelines. The GRADE methodology was used to rate the level of evidence. Twenty-eight studies were included in this review: 1 was a meta-analysis, 18 reported cohort outcomes, 4 retrospectively compared HIPEC regimens, and 5 were guidelines. Six HIPEC regimens were found, 4 with one drug (cisplatin, mitomycine-C, carboplatin, oxaliplatin), 2 using two drugs (cisplatin-doxorubicin or cisplatin-mitomycine-C). Cisplatin, up to 250 mg/m² over 90 min, appeared as the key HIPEC drug with a toxicity profile well controlled by the concomitant intravenous perfusion of sodium thiosulfate. Comparative studies tended to show that a bi-drug regimen led to better long-term oncologic outcomes, with cisplatin 50 mg/m² plus doxorubicin 15 mg/m² being safe and more efficient. This late protocol was the most widely used and recommended in 3 out of 4 international guidelines. Cisplatin was the preferred drug for HIPEC in DMPM patients. Most of the time, it was combined with doxorubicin for 90 min. A harmonization of protocols and further comparative studies are needed to optimize HIPEC regimen choice.

Miller J, Wynn WH (1908) A malignant tumour arising from the endothelium of the peritoneum, and producing a mucoid ascitic fluid. J Pathol 12(2):267–278. https://doi.org/10.1002/path.1700120212CrossRef

Greenbaum A, Alexander HR (2020) Peritoneal mesothelioma. Transl Lung Cancer Res 9(1):S120–S132. https://doi.org/10.21037/tlcr.2019.12.15CrossRefPubMedPubMedCentral

Boffetta P (2007) Epidemiology of peritoneal mesothelioma: a review. Ann Oncol 18(6):985–990. https://doi.org/10.1093/annonc/mdl345CrossRefPubMed

Husain AN, Colby TV, Ordóñez NG et al (2017) Guidelines for pathologic diagnosis of malignant mesothelioma: 2017 update of the consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med. https://doi.org/10.5858/arpa.2017-0124-RACrossRefPubMedPubMedCentral

the RENAPE Network, Vogin G, Hettal L et al (2019) Well-differentiated papillary mesothelioma of the peritoneum: a retrospective study from the RENAPE observational registry. Ann Surg Oncol 26(3):852–860. https://doi.org/10.1245/s10434-018-07153-2CrossRef

Nizri E, Baratti D, Guaglio M et al (2018) Multicystic mesothelioma: operative and long-term outcomes with cytoreductive surgery and hyperthermic intra peritoneal chemotherapy. Eur J Surg Oncol 44(7):1100–1104. https://doi.org/10.1016/j.ejso.2018.03.004CrossRefPubMed

Antman KH, Blum RH, Greenberger JS, Flowerdew G, Skarin AT, Canellos GP (1980) Multimodality therapy for malignant mesothelioma based on a study of natural history. Am J Med 68(3):356–362CrossRefPubMed

Berghmans T, Paesmans M, Lalami Y et al (2002) Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis. Lung Cancer 38(2):111–121CrossRefPubMed

Jänne PA, Wozniak AJ, Belani CP et al (2005) Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program. Clin Lung Cancer 7(1):40–46. https://doi.org/10.3816/CLC.2005.n.020CrossRefPubMed

10.

Carteni G, Manegold C, Garcia GM et al (2009) Malignant peritoneal mesothelioma-results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent. Lung Cancer 64(2):211–218. https://doi.org/10.1016/j.lungcan.2008.08.013CrossRefPubMed

11.

Vogelzang NJ, Rusthoven JJ, Symanowski J et al (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21(14):2636–2644. https://doi.org/10.1200/JCO.2003.11.136CrossRefPubMed

12.

Yan TD, Deraco M, Baratti D et al (2009) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol 27(36):6237–6242. https://doi.org/10.1200/JCO.2009.23.9640CrossRefPubMed

13.

Helm JH, Miura JT, Glenn JA et al (2014) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis. Ann Surg Oncol. https://doi.org/10.1245/s10434-014-3978-xCrossRefPubMed

14.

Verma V, Sleightholm RL, Rusthoven CG et al (2018) Malignant peritoneal mesothelioma: national practice patterns, outcomes, and predictors of survival. Ann Surg Oncol 25(7):2018–2026. https://doi.org/10.1245/s10434-018-6499-1CrossRefPubMed

15.

Bijelic L, Darcy K, Stodghill J, Tian C, Cannon T (2020) Predictors and outcomes of surgery in peritoneal mesothelioma: an analysis of 2000 patients from the National Cancer Database. Ann Surg Oncol 39(7):576–579. https://doi.org/10.1245/s10434-019-08138-5CrossRef

16.

Yan TD, Deraco M, Elias D et al (2011) A novel tumor-node-metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi-institutional database*. Cancer 117(9):1855–1863. https://doi.org/10.1002/cncr.25640CrossRefPubMed

17.

Kusamura S, Torres Mesa PA, Cabras A, Baratti D, Deraco M (2016) The role of Ki-67 and pre-cytoreduction parameters in selecting diffuse malignant peritoneal mesothelioma (DMPM) patients for cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol 23(5):1468–1473. https://doi.org/10.1245/s10434-015-4962-9CrossRefPubMed

18.

Alexander HR, Bartlett DL, Pingpank JF et al (2013) Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma. Surgery 153(6):779–786. https://doi.org/10.1016/j.surg.2013.01.001CrossRefPubMed

19.

Ceelen WP, Flessner MF (2010) Intraperitoneal therapy for peritoneal tumors: biophysics and clinical evidence. Nat Rev Clin Oncol 7(2):108–115. https://doi.org/10.1038/nrclinonc.2009.217CrossRefPubMed

20.

Turaga KK, Deraco M, Alexander HR (2017) Current management strategies for peritoneal mesothelioma. Int J Hyperthermia 33(5):579–581. https://doi.org/10.1080/02656736.2017.1320591CrossRefPubMed

21.

Sugarbaker PH, Chang D (2017) Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival. Eur J Surg Oncol 43(7):1228–1235. https://doi.org/10.1016/j.ejso.2017.01.009CrossRefPubMed

22.

Le Roy F, Gelli M, Hollebecque A et al (2017) Conversion to complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma after bidirectional chemotherapy. Ann Surg Oncol 24(12):3640–3646. https://doi.org/10.1245/s10434-017-6033-xCrossRefPubMed

23.

Giger-Pabst U, Demtröder C, Falkenstein TA et al (2018) Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for the treatment of malignant mesothelioma. BMC Cancer 18(1):442. https://doi.org/10.1186/s12885-018-4363-0CrossRefPubMedPubMedCentral

24.

Jacquet P, Sugarbaker PH (1996) Peritoneal-plasma barrier. In: Peritoneal Carcinomatosis: Principles of Management. Vol 82. Cancer Treatment and Research. Boston, MA: Springer, Boston, MA;53–63. https://doi.org/10.1007/978-1-4613-1247-5_4.

25.

Dedrick RL, Myers CE, Bungay PM, DeVita VT (1978) Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 62(1):1–11PubMed

26.

Dedrick RL (1985) Theoretical and experimental bases of intraperitoneal chemotherapy. Semin Oncol 12(3 Suppl 4):1–6PubMed

27.

Spratt JS, Adcock RA, Muskovin M, Sherrill W, McKeown J (1980) Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res 40(2):256–260PubMed

28.

Yan TD, Welch L, Black D, Sugarbaker PH (2007) A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann Oncol 18(5):827–834. https://doi.org/10.1093/annonc/mdl428CrossRefPubMed

29.

Ma GY, Bartlett DL, Reed E et al (1997) Continuous hyperthermic peritoneal perfusion with cisplatin for the treatment of peritoneal mesothelioma. Cancer J Sci Am 3(3):174–179PubMed

30.

Lemoine L, Sugarbaker P, Van Der Speeten K (2017) Drugs, doses, and durations of intraperitoneal chemotherapy: standardising HIPEC and EPIC for colorectal, appendiceal, gastric, ovarian peritoneal surface malignancies and peritoneal mesothelioma. Int J Hyperth 33(5):582–592. https://doi.org/10.1080/02656736.2017.1291999CrossRef

31.

Kusamura S, Kepenekian V, Villeneuve L et al (2020) Peritoneal mesothelioma: PSOGI/EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. Eur J Surg Oncol. https://doi.org/10.1016/j.ejso.2020.02.011CrossRefPubMed

32.

Chicago Consensus Working Group (2020) The Chicago consensus on peritoneal surface malignancies: management of peritoneal mesothelioma. Ann Surg Oncol 19(1):1–6. https://doi.org/10.1245/s10434-020-08324-wCrossRef

33.

Latin American Registry of Peritoneal Diseases – LARPD participants (2018) Current practice of Latin American centers in the treatment of peritoneal diseases with cytoreductive surgery with HIPEC. Eur J Surg Oncol 44(11):1800–1804. https://doi.org/10.1016/j.ejso.2018.06.029CrossRef

34.

Batista TP, Sarmento BJQ, Loureiro JF et al (2017) A proposal of Brazilian Society of Surgical Oncology (BSSO/SBCO) for standardizing cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) procedures in Brazil: pseudomixoma peritonei, appendiceal tumors and malignant peritoneal mesothelioma. Rev Col Bras Cir 44(5):530–544. https://doi.org/10.1590/0100-69912017005016CrossRefPubMed

35.

Li Y, Zhou Y-F, Liang H et al (2016) Chinese expert consensus on cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignancies. World J Gastroenterol 22(30):6906–6916. https://doi.org/10.3748/wjg.v22.i30.6906CrossRefPubMedPubMedCentral

36.

Lurvink RJ, Villeneuve L, Govaerts K et al (2019) The Delphi and GRADE methodology used in the PSOGI 2018 consensus statement on pseudomyxoma peritonei and peritoneal mesothelioma. Eur J Surg Oncol. https://doi.org/10.1016/j.ejso.2019.03.012CrossRefPubMed

37.

Chicago Consensus Working Group (2020) The Chicago consensus on peritoneal surface malignancies: methodology. Ann Surg Oncol 1–2. https://doi.org/10.1245/s10434-020-08317-9.

38.

Guyatt GH, Oxman AD, Kunz R et al (2008) Going from evidence to recommendations. BMJ 336(7652):1049–1051. https://doi.org/10.1136/bmj.39493.646875.AECrossRefPubMedPubMedCentral

39.

Malgras B, Gayat E, Aoun O et al (2018) Impact of combination chemotherapy in peritoneal mesothelioma hyperthermic intraperitoneal chemotherapy (HIPEC): the RENAPE study. Ann Surg Oncol 25(11):3271–3279. https://doi.org/10.1245/s10434-018-6631-2CrossRefPubMed

40.

Yurttas C, Hoffmann G, Tolios A et al (2018) Systematic review of variations in hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal metastasis from colorectal cancer. JCM 7(12):567. https://doi.org/10.3390/jcm7120567CrossRefPubMedPubMedCentral

41.

Atkins D, Best D, Briss PA et al (2004) Grading quality of evidence and strength of recommendations. BMJ 328(7454):1490. https://doi.org/10.1136/bmj.328.7454.1490CrossRefPubMed

42.

Guyatt G, Oxman AD, Akl EA et al (2011) GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 64(4):383–394. https://doi.org/10.1016/j.jclinepi.2010.04.026CrossRefPubMed

43.

Liberati A, Altman DG, Tetzlaff J et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 6(7):e1000100. https://doi.org/10.1371/journal.pmed.1000100CrossRefPubMedPubMedCentral

44.

Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(7):e1000097. https://doi.org/10.1371/journal.pmed.1000097CrossRefPubMedPubMedCentral

45.

Kyziridis D, Hristakis C, Kalakonas A et al (2019) Ten-year experience with peritoneal mesothelioma. J BUON 24(1):391–396PubMed

46.

Gilani SNS, Mehta A, García-Fadrique A et al (2018) Outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma and predictors of survival. Int J Hyperthermia 58:1–7. https://doi.org/10.1080/02656736.2018.1434902CrossRef

47.

Stamou K, Tsamis D, Pallas N et al (2015) Treating peritoneal mesothelioma with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy A case series and review of the literature. Int J Hyperthermia 31(8):850–856. https://doi.org/10.3109/02656736.2015.1075071CrossRefPubMed

48.

Ihemelandu C, Bijelic L, Sugarbaker PH (2014) Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent or progressive diffuse malignant peritoneal mesothelioma: clinicopathologic characteristics and survival outcome. Ann Surg Oncol 22(5):1680–1685. https://doi.org/10.1245/s10434-014-3977-yCrossRefPubMed

49.

Robella M, Vaira M, Mellano A et al (2014) Treatment of diffuse malignant peritoneal mesothelioma (DMPM) by cytoreductive surgery and HIPEC. Minerva Chir 69(1):9–15PubMed

50.

Baratti D, Kusamura S, Cabras AD, Bertulli R, Hutanu I, Deraco M (2013) Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC). Eur J Cancer 49(15):3140–3148. https://doi.org/10.1016/j.ejca.2013.05.027CrossRefPubMed

51.

Chua TC, Yan TD, Morris DL (2009) Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: the Australian experience. J Surg Oncol 99(2):109–113. https://doi.org/10.1002/jso.21177CrossRefPubMed

52.

Yan TD, Yoo D, Sugarbaker PH (2006) Significance of lymph node metastasis in patients with diffuse malignant peritoneal mesothelioma. Eur J Surg Oncol 32(9):948–953. https://doi.org/10.1016/j.ejso.2006.05.009CrossRefPubMed

53.

Deraco M, Nonaka D, Baratti D et al (2006) Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol 13(2):229–237. https://doi.org/10.1245/ASO.2006.03.045CrossRefPubMed

54.

Sebbag G, Yan H, Shmookler BM, Chang D, Sugarbaker PH (2000) Results of treatment of 33 patients with peritoneal mesothelioma. Br J Surg 87(11):1587–1593. https://doi.org/10.1046/j.1365-2168.2000.01571.xCrossRefPubMed

55.

Huang Y, Alzahrani NA, Liauw W, Morris DL (2015) Repeat cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent diffuse malignant peritoneal mesothelioma. Eur J Surg Oncol 41(10):1373–1378. https://doi.org/10.1016/j.ejso.2015.07.004CrossRefPubMed

56.

Magge D, Zenati MS, Austin F et al (n.d) Malignant peritoneal mesothelioma: prognostic factors and oncologic outcome analysis. Ann Surg Oncol. s10.1245/s10434–013–3358-y.

57.

Brigand C, Monneuse O, Mohamed F et al (2006) Peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy: results of a prospective study. Ann Surg Oncol 13(3):405–412. https://doi.org/10.1245/ASO.2006.05.041CrossRefPubMed

58.

Schaub NP, Alimchandani M, Quezado M et al (2013) A novel nomogram for peritoneal mesothelioma predicts survival. Ann Surg Oncol 20(2):555–561. https://doi.org/10.1245/s10434-012-2651-5CrossRefPubMed

59.

Park BJ, Alexander HR, Libutti SK et al (1999) Treatment of primary peritoneal mesothelioma by continuous hyperthermic peritoneal perfusion (CHPP). Ann Surg Oncol 6(6):582–590. https://doi.org/10.1007/s10434-999-0582-6CrossRefPubMed

60.

Feldman AL, Libutti SK, Pingpank JF et al (2003) Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol 21(24):4560–4567. https://doi.org/10.1200/JCO.2003.04.150CrossRefPubMed

61.

Loggie BW, Fleming RA, McQuellon RP, Russell GB, Geisinger KR, Levine EA (2001) Prospective trial for the treatment of malignant peritoneal mesothelioma. Am Surg 67(10):999–1003CrossRefPubMed

62.

Hubert J, Thiboutot E, Dubè P, Cloutier A-S, Drolet P, Sideris L (2015) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with oxaliplatin for peritoneal mesothelioma: preliminary results and survival analysis. Surg Oncol 24(1):41–46. https://doi.org/10.1016/j.suronc.2014.12.002CrossRefPubMed

63.

Blackham AU, Shen P, Stewart JH, Russell GB, Levine EA (2010) Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for malignant peritoneal mesothelioma: mitomycin versus cisplatin. Ann Surg Oncol 17(10):2720–2727. https://doi.org/10.1245/s10434-010-1080-6CrossRefPubMed

64.

Shetty SJ, Bathla L, Govindarajan V, Thomas P, Loggie BW (2014) Comparison of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with mitomycin or carboplatin for diffuse malignant peritoneal mesothelioma. Am Surg 80(4):348–352. https://doi.org/10.1177/000313481408000415CrossRefPubMed

65.

Alexander HR, Fraker DL (1996) Treatment of peritoneal carcinomatosis by continuous hyperthermic peritoneal perfusion with cisplatin. Cancer Treat Res 81(Chapter 5):41–50. https://doi.org/10.1007/978-1-4613-1245-1_5CrossRefPubMed

66.

Howell SB, Pfeifle CL, Wung WE et al (1982) Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med 97(6):845–851. https://doi.org/10.7326/0003-4819-97-6-845CrossRefPubMed

67.

Howell SB, Pfeifle CE, Wung WE, Olshen RA (1983) Intraperitoneal cis-diamminedichloroplatinum with systemic thiosulfate protection. Cancer Res 43(3):1426–1431PubMed

68.

Bartlett DL, Buell JF, Libutti SK et al (1998) A phase I trial of continuous hyperthermic peritoneal perfusion with tumor necrosis factor and cisplatin in the treatment of peritoneal carcinomatosis. Cancer 83(6):1251–1261CrossRefPubMed

69.

Loggie BW, Fleming RA, McQuellon RP, Russell GB, Geisinger KR (2000) Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for disseminated peritoneal cancer of gastrointestinal origin. Am Surg 66(6):561–568CrossRefPubMed

70.

Loggie BW (2001) Malignant peritoneal mesothelioma. Curr Treat Options Oncol 2(5):395–399. https://doi.org/10.1007/s11864-001-0044-2CrossRefPubMed

71.

Elias D, Bonnay M, Puizillou JM et al (2002) Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann Oncol 13(2):267–272CrossRefPubMed

72.

Helm CW, Richard SD, Pan J et al (2010) Hyperthermic intraperitoneal chemotherapy in ovarian cancer: first report of the HYPER-O registry. Int J Gynecol Cancer 20(1):61–69. https://doi.org/10.1111/IGC.0b013e3181c50cdeCrossRefPubMed

73.

Mikkelsen MS, Blaakaer J, Petersen LK, Schleiss LG, Iversen LH (2020) Pharmacokinetics and toxicity of carboplatin used for hyperthermic intraperitoneal chemotherapy (HIPEC) in treatment of epithelial ovarian cancer. Pleura Peritoneum 5(4):20200137. https://doi.org/10.1515/pp-2020-0137CrossRefPubMedPubMedCentral

74.

Barlogie B, Corry PM, Drewinko B (1980) In vitro thermochemotherapy of human colon cancer cells with cis-dichlorodiammineplatinum(II) and mitomycin C. Cancer Res 40(4):1165–1168PubMed

75.

Rossi CR, Foletto M, Mocellin S et al (2002) Hyperthermic intraoperative intraperitoneal chemotherapy with cisplatin and doxorubicin in patients who undergo cytoreductive surgery for peritoneal carcinomatosis and sarcomatosis: phase I study. Cancer 94(2):492–499. https://doi.org/10.1002/cncr.10176CrossRefPubMed

76.

Deraco M, Casali P, Inglese MG et al (2003) Peritoneal mesothelioma treated by induction chemotherapy, cytoreductive surgery, and intraperitoneal hyperthermic perfusion. J Surg Oncol 83(3):147–153. https://doi.org/10.1002/jso.10255CrossRefPubMed

77.

Chapel DB, Schulte JJ, Absenger G et al (2020) Malignant peritoneal mesothelioma: prognostic significance of clinical and pathologic parameters and validation of a nuclear-grading system in a multi-institutional series of 225 cases. Mod Pathol 39:1568–1616. https://doi.org/10.1038/s41379-020-00688-4CrossRef

78.

RENAPE Working Group, Votanopoulos KI, Sugarbaker P et al (2017) Is cytoreductive surgery with hyperthermic intraperitoneal chemotherapy justified for biphasic variants of peritoneal mesothelioma? Outcomes from the Peritoneal Surface Oncology Group International Registry. Ann Surg Oncol 25(3):667–673. https://doi.org/10.1245/s10434-017-6293-5CrossRef

79.

Van Der Speeten K, Stuart OA, Chang D, Mahteme H, Sugarbaker PH (2011) Changes induced by surgical and clinical factors in the pharmacology of intraperitoneal mitomycin C in 145 patients with peritoneal carcinomatosis. Cancer Chemother Pharmacol 68(1):147–156. https://doi.org/10.1007/s00280-010-1460-4CrossRefPubMed

80.

Fuso Nerini I, Roca E, Mannarino L, Grosso F, Frapolli R, D’Incalci M (2020) Is DNA repair a potential target for effective therapies against malignant mesothelioma? Cancer Treat Rev 90:102101. https://doi.org/10.1016/j.ctrv.2020.102101CrossRefPubMed

81.

Panou V, Gadiraju M, Wolin A et al (2018) Frequency of germline mutations in cancer susceptibility genes in malignant mesothelioma. J Clin Oncol 36(28):2863–2871. https://doi.org/10.1200/JCO.2018.78.5204CrossRefPubMedPubMedCentral

82.

Deraco M, Baratti D, Hutanu I, Bertuli R, Kusamura S (2013) The role of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 20(4):1093–1100. https://doi.org/10.1245/s10434-012-2845-xCrossRefPubMed

83.

Naffouje SA, Tulla KA, Salti GI (2018) The impact of chemotherapy and its timing on survival in malignant peritoneal mesothelioma treated with complete debulking. Med Oncol 35(5):69. https://doi.org/10.1007/s12032-018-1125-4CrossRefPubMed

84.

Kepenekian V, Elias D, Passot G et al (2016) Diffuse malignant peritoneal mesothelioma: evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE Database: multi-institutional retrospective study. Eur J Cancer 65:69–79. https://doi.org/10.1016/j.ejca.2016.06.002CrossRefPubMed

85.

Zakris EL, Dewhirst MW, Riviere JE, Hoopes PJ, Page RL, Oleson JR (1987) Pharmacokinetics and toxicity of intraperitoneal cisplatin combined with regional hyperthermia. J Clin Oncol 5(10):1613–1620. https://doi.org/10.1200/JCO.1987.5.10.1613CrossRefPubMed

86.

Wallner KE, Li GC (1987) Effect of drug exposure duration and sequencing on hyperthermic potentiation of mitomycin-C and cisplatin. Cancer Res 47(2):493–495PubMed

87.

Markman M, Kelsen D (1992) Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma. J Cancer Res Clin Oncol 118(7):547–550CrossRefPubMed

88.

Langer CJ, Rosenblum N, Hogan M et al (1993) Intraperitoneal cisplatin and etoposide in peritoneal mesothelioma: favorable outcome with a multimodality approach. Cancer Chemother Pharmacol 32(3):204–208CrossRefPubMed

89.

Laplace N, Kepenekian V, Friggeri A et al (2020) Sodium thiosulfate protects from renal impairement following hyperthermic intraperitoneal chemotherapy (HIPEC) with Cisplatin. Int J Hyperthermia 37(1):897–902. https://doi.org/10.1080/02656736.2020.1795277CrossRefPubMed

90.

Koga S, Hamazoe R, Maeta M, Shimizu N, Kanayama H, Osaki Y (1984) Treatment of implanted peritoneal cancer in rats by continuous hyperthermic peritoneal perfusion in combination with an anticancer drug. Cancer Res 44(5):1840–1842PubMed

91.

Koga S, Hamazoe R, Maeta M, Shimizu N, Murakami A, Wakatsuki T (1988) Prophylactic therapy for peritoneal recurrence of gastric cancer by continuous hyperthermic peritoneal perfusion with mitomycin C. Cancer 61(2):232–237. https://doi.org/10.1002/1097-0142(19880115)61:2%3c232::aid-cncr2820610205%3e3.0.co;2-uCrossRefPubMed

92.

Fujimoto S, Shrestha RD, Kokubun M et al (1989) Clinical trial with surgery and intraperitoneal hyperthermic perfusion for peritoneal recurrence of gastrointestinal cancer. Cancer 64(1):154–160CrossRefPubMed

93.

Fujimoto S, Shrestha RD, Kokubun M et al (1990) Positive results of combined therapy of surgery and intraperitoneal hyperthermic perfusion for far-advanced gastric cancer. Ann Surg 212(5):592–596. https://doi.org/10.1097/00000658-199011000-00005CrossRefPubMedPubMedCentral

94.

Gilly FN, Sayag AC, Carry PY et al (1991) Intra-peritoneal chemo-hyperthermia (CHIP): a new therapy in the treatment of the peritoneal seedings. Preliminary report. Int Surg 76(3):164–167PubMed

95.

Gilly FN, Carry PY, Sayag AC et al (1994) Regional chemotherapy (with mitomycin C) and intra-operative hyperthermia for digestive cancers with peritoneal carcinomatosis. Hepatogastroenterology 41(2):124–129PubMed

96.

Jacquet P, Averbach A, Stephens AD, Stuart OA, Chang D, Sugarbaker PH (1998) Heated intraoperative intraperitoneal mitomycin C and early postoperative intraperitoneal 5-fluorouracil: pharmacokinetic studies. Oncology 55(2):130–138. https://doi.org/10.1159/000011847CrossRefPubMed

97.

Smeenk RM, Verwaal VJ, Zoetmulder FAN (2006) Toxicity and mortality of cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in pseudomyxoma peritonei–a report of 103 procedures. Eur J Surg Oncol 32(2):186–190. https://doi.org/10.1016/j.ejso.2005.08.009CrossRefPubMed

98.

Sugarbaker PH, Alderman R, Edwards G et al (2006) Prospective morbidity and mortality assessment of cytoreductive surgery plus perioperative intraperitoneal chemotherapy to treat peritoneal dissemination of appendiceal mucinous malignancy. Ann Surg Oncol 13(5):635–644. https://doi.org/10.1245/ASO.2006.03.079CrossRefPubMed

99.

Yan TD, Black D, Savady R, Sugarbaker PH (2006) Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma. J Clin Oncol 24(24):4011–4019. https://doi.org/10.1200/JCO.2006.07.1142CrossRefPubMed

100.

Schnake KJ, Sugarbaker PH, Yoo D (1999) Neutropenia following perioperative intraperitoneal chemotherapy. Tumori J 85(1):41–46CrossRef

101.

Lambert LA, Armstrong TS, Lee JJ et al (2009) Incidence, risk factors, and impact of severe neutropenia after hyperthermic intraperitoneal mitomycin C. Ann Surg Oncol 16(8):2181–2187. https://doi.org/10.1245/s10434-009-0523-4CrossRefPubMedPubMedCentral

Titel: Peritoneal Mesothelioma: Systematic Review of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Protocol Outcomes
verfasst von: Vahan Kepenekian
Olivia Sgarbura
Frederic Marchal
Laurent Villeneuve
Olivier Glehen
Shigeki Kusamura
Marcello Deraco
Publikationsdatum: 04.03.2023
Verlag: Springer India
Erschienen in: Indian Journal of Surgical Oncology / Ausgabe Sonderheft 1/2023
Print ISSN: 0975-7651
Elektronische ISSN: 0976-6952
DOI: https://doi.org/10.1007/s13193-023-01728-6

Neu im Fachgebiet Chirurgie

23.04.2024 | Ablationstherapie | Nachrichten

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 | Appendizitis | Nachrichten

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 | Operationsvorbereitung | Nachrichten

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Ureterstriktur: Innovative OP-Technik bewährt sich

weitere anzeigen

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare

CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare

CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske

Dr. med. Benjamin Meyknecht

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare

CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Sonderheft 1/2023

Refractory Hypotension and Rapid Onset AKI: Deadly Complication After Doxorubicin and Mitomycin-C HIPEC Therapy

Very Rare Peritoneal Surface Malignancies

First Case of Abdominal and Tunica Vaginalis Multicystic Benign Mesothelioma: Management and Review of Literature

Bidirectional Chemotherapy in Advanced Colorectal Cancer Peritoneal Metastases

Multi-omics Analysis Classifies Colorectal Cancer into Distinct Methylated Immunogenic and Angiogenic Subtypes Based on Anatomical Laterality

Histopathological Evaluation and Molecular Diagnostic Tests for Peritoneal Metastases with Unknown Primary Site—a Review

Neu im Fachgebiet Chirurgie

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Hinter dieser Appendizitis steckte ein Erreger

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

Ureterstriktur: Innovative OP-Technik bewährt sich

Update Chirurgie

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

S2e-Leitlinie „Distale Radiusfraktur“

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“